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Blockade of CD11a by Efalizumab in Psoriasis
Patients Induces a Unique State of T-Cell
Hyporesponsiveness
Emma Guttman-Yassky1,3, Yulia Vugmeyster2,3,4, Michelle A. Lowes1, Francesca Chamian1,
Toyoko Kikuchi1, Mark Kagen1, Patricia Gilleaudeau1, Edmund Lee1, Brisdell Hunte2, Kathy Howell2,
Wolfgang Dummer2, Sarah C. Bodary2,5 and James G. Krueger1
Efalizumab (anti-CD11a) interferes with LFA-1/ICAM-1 binding and inhibits several key steps in psoriasis
pathogenesis. This study characterizes the effects of efalizumab on T-cell activation responses and expression of
surface markers on human circulating psoriatic T cells during a therapeutic trial. Our data suggest that
efalizumab may induce a unique type of T-cell hyporesponsiveness, directly induced by LFA-1 binding, which is
distinct from conventional anergy described in animal models. Direct activation of T cells through different
activating receptors (CD2, CD3, CD3/28) is reduced, despite T cells being fully viable. This hyporesponsiveness
was spontaneously reversible after withdrawal of the drug, and by IL-2 in vitro. In contrast to the state of anergy,
Caþ 2 release is intact during efalizumab binding. Furthermore, lymphocyte function-associated antigen-1
(LFA-1) blockade resulted in an unexpected downregulation of a broad range of surface molecules, including
the T-cell receptor complex, co-stimulatory molecules, and integrins unrelated to LFA-1, both in the peripheral
circulation and in diseased skin tissue. These observations provide evidence for the mechanism of action of
efalizumab. The nature of this T-cell hyporesponsiveness suggests that T-cell responses may be reduced during
efalizumab therapy, but are reversible after ceasing efalizumab treatment.
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INTRODUCTION
Lymphocyte function-associated antigen-1 (LFA-1) is a
heterodimeric glycoprotein belonging to the b2-integrin
family (Carlos and Harlan, 1994; Werther et al., 1996), also
known as aL-b2 or CD11a/CD18, which binds intracellular
adhesion molecules 1–3 (ICAM-1, ICAM-2, and ICAM-3).
LFA-1 plays a pivotal role in several important homeostatic
processes, including T lymphocyte recirculation, trafficking
to sites of inflammation, antigen presentation by dendritic
cells, and other cells such as activated keratinocytes (Stewart
et al., 1996; Hogg et al., 2003; Kinashi, 2005), and T-cell
co-stimulation (Van Seventer et al., 1990, 1991, 1992;
Kanner et al., 1993).
LFA-1 is a molecular target for therapeutic modulation of
immune responses in disease states, as tissue inflammation in
experimental models has been blocked by administration of
LFA-1 antibodies (Ferrara et al., 1990; Isobe et al., 1992;
Scheynius et al., 1993; Tanaka et al., 1993; Gordon et al.,
1995; Moriyama et al., 1996; Willenborg et al., 1996).
However, little is known about the therapeutic mechanisms of
targeting integrins in human subjects. This issue is important,
since the humanized anti-CD11a antibody (efalizumab) is
currently an approved agent for treatment of psoriasis vulgaris
(Gottlieb et al., 2002; Lebwohl et al., 2003). As psoriasis
affects about 25 million people in North America and Europe,
new psoriasis therapies are likely to be used in large numbers
of patients.
Anergy may be broadly defined as a functional state where
a T cell fails to react to its cognate antigen, and it is often
considered to be a mechanism to maintain peripheral
tolerance (Appleman and Boussiotis, 2003; Schwartz, 2003;
Macian et al., 2004). Additional features of anergic T cells
include a restoration of functional inactivity by exogenous
IL-2, and a lack of Ca2þ mobilization, which normally occurs
during T-cell activation.
This study was designed to characterize the effects
of efalizumab on T-cell activation responses and expression
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of T-cell surface molecules during a therapeutic trial.
Here we demonstrate two unexpected effects on T cells
obtained from psoriasis patients. First, direct stimulation
of T cells with mitogenic antibodies was significantly
decreased during active treatment (anti-CD2, anti-CD3, and
combined anti-CD3/CD28), but remained normal with
phorbol-12-myristate-3-acetate (PMA) and ionomycin. This
is in contrast to the increase in proliferative responses seen
with a polyclonal stimulus in murine T cells treated with
LFA-1 antibodies (Bohmig et al., 1994). Thus, only in
the human experiments were T cells hyporesponsive to
direct stimulation via surface molecules. Second, down-
regulation of numerous activation-controlling surface
molecules on T cells was produced by efalizumab treat-
ment, including those associated with the T-cell receptor
(TCR) complex, co-stimulatory pathways, and integrins
unrelated to LFA-1. Since both of these effects were not
anticipated from the study of LFA-1 antibodies in model
systems, they reinforce the need to study biologic effects of
new immune antagonists in human populations receiving
these agents.
RESULTS
In vivo, T-cell activation through anti-CD3-, anti-CD2-, and
anti-CD3/CD28 is inhibited by efalizumab (anti-CD11a)
We determined whether in vivo exposure of lymphocytes to
efalizumab reduced responsiveness through surface molecule
ligation. Anti-CD3 stimulation of peripheral blood lympho-
cytes from 12 untreated psoriatic patients showed dose-
dependent activation, as measured by increased expression
of CD69 on CD2-expressing lymphocytes (both mean
fluorescence intensity (MFI) and percent positive cells
increased) (Figure 1a). After 14 days of efalizumab treatment,
CD3-mediated activation was greatly reduced at all doses in
all subjects. This non-responsiveness of lymphocytes to
activation by anti-CD3 was maintained throughout the
treatment period with efalizumab (day 84). After washout of
efalizumab (day 168), CD3-mediated T-cell activation
returned to normal (Figure 1a), in line with re-expression of
CD11a on T cells (Figure 1b).
In a second group of 15 patients, we tested additional
activating stimuli, including soluble anti-CD3 antibody, a
mitogenic pair of anti-CD2 antibodies (T11.1 and T11.2), and
bead-bound anti-CD3 and anti-CD28 antibodies (Figure 1c
and d). Consistent with results in the first group of patients,
T-cell activation (CD69 upregulation) to soluble anti-CD3
antibodies was inhibited in all 15 patients (Po0.001; Figure
1d). T-cell activation induced by CD2 ligation was also
consistently inhibited during in vivo treatment with efalizu-
mab (P¼ 0.001). However, T-cell activation with a stronger
stimulus (bead-bound anti-CD3/anti-CD28 antibodies) in-
duced greater expression of CD69 compared with soluble
CD3 or CD2 antibodies (Figure 1c and d). Although eight
efalizumab-treated patients had reduced T-cell activation
responses to this combined stimulus (example shown
in Figure 1c), there was only about a 20% average reduction
in responses to CD3/CD28 activation (P¼ 0.37). The
hyporesponsiveness of T cells under efalizumab therapy
was seen in all patients, and this was unrelated to the
therapeutic efficacy.
We also examined T-cell activation induced by PMA and
ionomycin to determine whether T-cell hyporesponsiveness
in efalizumab-treated patients was due to deletion of cells
with activation potential (Figure 1e and f). We considered
that this might occur even in the setting of efalizumab-
induced relative leukocytosis, (Vugmeyster et al., 2004).
Upon PMA/ionomycin activation, virtually all T cells showed
increased expression of CD69, and neither the frequency of
cells showing activation (data not shown), nor the levels of
CD69 induced on individual cells, were reduced during
efalizumab treatment. This indicated that the activation
potential of the T cells was intact.
We next determined whether a functional response of T
cells was impaired by in vivo efalizumab treatment. Given
that IFN-g-producing T cells are excessively expanded and
activated in psoriasis patients (Szegedi et al., 2003), we
examined T cells for their ability to synthesize this cytokine in
response to activation by soluble anti-CD3 or anti-CD2
antibodies, by bead-bound anti-CD3/anti-CD28 antibodies,
and by PMA/ionomycin activation before and during treat-
ment with efalizumab (Figure 2). With soluble anti-CD3
antibodies, T cells from psoriasis patients treated with
efalizumab for 2 weeks showed consistently reduced ability
to synthesize IFN-g (Po0.02) (Figure 2a–c). As with induction
of CD69, nearly complete inhibition of IFN-g synthesis in
response to CD3 ligation was observed, whereas a lesser
inhibition of response to CD3/CD28 co-ligation was
measured (data not shown). The average frequency of
IFN-g-producing cells was not altered by efalizumab treat-
ment when PMA/ionomycin was used as the activation
stimulus (P¼ 0.2), confirming the presence of responsive
T cells, cell viability, and the ability of the cells to produce
this cytokine (Figure 2b and c).
The differential T-cell activation response to soluble anti-
CD3 antibodies versus PMA/ionomycin suggested that early
events in signal transduction through the TCR receptor
complex might be blocked by efalizumab exposure in vivo.
In contrast, T-cell anergy induced by other methods is
associated with reduction in the signaling cascade that leads
to intracellular calcium release (Haque et al., 1998). To test
whether efalizumab induced a similar alteration in T-cell
responsiveness, intracellular calcium release was monitored
by Indo-1, a protein which fluoresces at different wavelengths
depending on its binding to Caþ 2. As illustrated for two
patients with psoriasis in Figure 3b, T cells showed excellent
Caþ 2 flux responses to stimulation with anti-CD3 antibody
plus surface cross-linking of this antibody with anti-mouse
IgG. Those results were equivalent to the Caþ 2 flux responses
from normal volunteers (Figure 3a). T cells taken from
patients at 2 weeks of treatment with efalizumab had no
reduction in the intracellular calcium release response,
including both the kinetics of release and the overall
magnitude of the response. Similar results to those illustrated
in Figure 3 were observed in eight sequential patients studied
that were stimulated with anti-CD3 (Figure S1) or anti-CD3
and anti-CD2 (Figure S2).
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In vitro, T-cell activation through anti-CD3 and anti-CD3/CD28
is inhibited by efalizumab (anti-CD11a), and this
hyporesponsiveness is instantly reversed by IL-2
Anti-CD3 stimulation of T-lymphocytes in whole blood from
healthy volunteers was measured by induced expression of
CD69 on CD2-expressing lymphocytes. In vitro incubation
with efalizumab resulted in dose-dependent inhibition of the
activation response, with the IC50 of B0.1–0.3 mgml
1
(Figure 4a). Furthermore, the maximal inhibition was
measured near the levels of efalizumab that would occur
in vivo in psoriasis patients (B10 mgml1) (Figure 4a). The
murine monoclonal MHM24 (parent of efalizumab) and Fab
fragments of efalizumab also strongly inhibited the T-cell
proliferation response to CD3 ligation (Figure 4b). Similarly,
T-cell proliferation triggered by CD3 and CD28 co-ligation
was impaired in the presence of efalizumab and this
inhibition was fully reversed by IL-2 (Figure 4c).
Peripheral blood T cells show down-modulation of cell-surface
expression of CD3, CD2, TCR, CD4, CD8, VLA-4, and CD28 in
efalizumab (anti-CD11a)-treated patients
As two types of intracellular activation systems (calcium
response and PMA/ionomycin response) were functioning
correctly in T cells from efalizumab-treated patients, we next
analyzed the expression of cell-surface molecules that might
control T-cell activation responses before and during
efalizumab treatment. We examined the levels of an array
of different surface molecules on both the peripheral T cells
and on T cells obtained from psoriasis skin lesions by short-
term incubation.
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Figure 1. Inhibition of ex vivo anti-CD3-, anti-CD2, and anti-CD3/anti-CD28-induced activation of circulating T cells in efalizumab-treated psoriatic patients.
(a) CD69 levels (MFI) on T cells stimulated ex vivo with increasing concentrations of anti-CD3 antibody at different time points during (up to day 84) and after
efalizumab treatment. (b) CD11a expression on unstimulated T cells to assess CD11a saturation throughout the treatment period (up to day 84) and upon
efalizumab washout. (c) A set of representative dot plots illustrates that efalizumab treatment by week 2 inhibits T-cell activation (CD69 MFI) induced by all
three cell-surface stimuli, although less so with anti-CD3/CD28 stimuli. (d) Mean percent change in CD69 MFI with various stimuli, in patients on efalizumab
treatment compared with baseline. *Indicates Po0.05. (e) Mean change in CD69 MFI with PMA/ionomycin stimulation on days 0 and 14 of efalizumab
treatment showing no difference in T-cell activation by this stimuli. (f) A representative CD69 histogram for PMA/ionomycin stimulation illustrates that
efalizumab treatment (black line, day 14) has no effect on PMA/ionomycin-mediated upregulation of CD69, as compared with baseline (gray line, day 0). Dotted
line corresponds to the baseline CD69 expression on unstimulated T cells.
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Previous studies have demonstrated that efalizumab binds
to CD11a and saturates binding sites and also has the ability
to downregulate both subunits of LFA-1 (CD11a and CD18)
(Vugmeyster et al., 2004). First, we studied changes in surface
antigens in peripheral blood of efalizumab-treated patients
(Figure 5b–g, left side). Saturation of CD11a on circulating T
cells was determined using a competing custom-conjugated
FITC-efalizumab antibody (Figure 5b), whereas downregula-
tion of CD11a was assessed with CD11a (clone 25.3), which
binds to a non-competitive epitope (Figure 5c). There was
almost complete saturation of CD11a with efalizumab during
therapy (Po0.00001) (Figure 5b). As expected, both subunits
of LFA-1 were significantly downregulated in all subjects. The
expression of CD11a was reduced by 85–73% (Po0.0001),
whereas the expression of CD18 was reduced by 76–63%
(Po0.0001).
Other surface receptors unrelated to LFA-1 were also
quantified (Figure 5). The levels of CD3 were not affected by
efalizumab (P40.2) (Figure 5d and e). The majority of
patients showed downregulation of CD28 on circulating T
cells with a mean reduction of 22% (P¼0.02). Both the
CD28hi and CD28lo populations were reduced (Figure 5d).
We were particularly interested in studying the modulation of
VLA-4 (CD29 and CD49d) during efalizumab therapy, as it is
an important alternative integrin for lymphocyte trafficking in
the presence of LFA-1 blockade. MFI values for both
components of VLA-4 on circulating CD3þCD8þ cells
decreased significantly at day 14 (Figure 5e and f, Figure 6).
There was a 52–76% reduction in CD29 (Po0.007) and a
75–68% reduction in CD49d (P¼0.001) (Figure 5c and f).
The CD29hi population was largely eliminated, whereas the
CD29lo population was less affected (Figure 5f and g).
Similarly, the CD49dhi population was significantly
decreased by approximately 80% (P¼0.006) (Figure 6).
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ability to synthesize IFN-g in response to anti-CD3 antibody after 2 weeks of
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Figure 3. Assessment of intracellular signalling through TCR/CD3 complex.
Normal anti-CD3-mediated intracellular Ca2þ flux response in T cells from
efalizumab-treated patient PBMCs that were loaded with Indo-1, activated
with anti-CD3, and cross-linked with an anti-mouse IgG. The Caþ2 flux was
measured as the ratio between bound and unbound Indo-1 versus time.
(a) Intracellular Caþ2 flux from a representative normal volunteer pre- and
post-stimulation with OKT3 (anti-CD3) and T11 (anti-CD2). (b and c) T cell
intracellular Caþ2 flux responses from two representative patients are
presented before and after efalizumab therapy.
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CD2 levels were significantly downregulated (although
still quantifiable) with efalizumab treatment by 32–50%
(Po0.03) (Figure 5a and g). The expression of the CD8
co-receptor on CD3þCD8þ T lymphocytes was significantly
decreased as early as day 14, with 58–65% reduction
(Po0.003). CD8 MFI values showed a clear trend of recovery
to pretreatment levels after therapy termination (Figure 6c).
Finally, there was also a significant down-modulation of CD4
and TCR to about 64–82% of baseline values (data not
shown).
Psoriatic lesional T cells show down-modulation of cell-surface
expression of LFA-1, CD28þ , CD29þ , CD8þ and CD3þ in
efalizumab (anti-CD11aþ )-treated patients
T cells obtained from psoriatic skin lesions before and during
efalizumab therapy were examined for the expression of cell-
surface markers involved in T-cell trafficking and activation
for comparison to circulating T cells (Figure 5a and b–g, right
side). Not all the changes observed in circulating T-cell
surface antigens described above were present in psoriatic
lesional T cells.
CD11a and CD18 median levels were 55 and 44% of
baseline, respectively (P¼0.001), which was a pattern
similar to circulating T cells, but greater in magnitude. There
was also an extremely consistent down-modulation of CD28
expression to approximately 68% of the baseline level
(P¼0.001), which was also a greater reduction relative to
that on circulating T cells. CD29 levels were moderately but
significantly reduced to 83% of baseline (P¼0.01). CD8
expression was significantly reduced to about 78% of
baseline (P¼ 0.03). However, unlike peripheral blood
lymphocytes, CD3 expression on T cells in psoriatic lesions
was significantly decreased in 8 out of 14 cases. Overall the
mean reduction in the MFI for the CD3 marker was 22%
(P¼0.0004). There were no significant changes in the
expression of TCR, CD2, CD4, and CD49d. Hence, although
efalizumab saturates T-cell CD11a and downregulates LFA-1
in both circulating and skin compartments, there are
interesting differences in the effects on other surface
molecules. For example, the mean reduction in CD28 is
higher in skin infiltrating T cells, whereas changes in CD2
and TCR are apparent only in circulating cells.
DISCUSSION
In this study, we describe a unique T-cell hyporesponsiveness
induced by anti-CD11 binding through the humanized
monoclonal therapeutic antibody efalizumab. We postulate
that efalizumab directly induces an alteration of the T-cell
activation threshold for CD3 or CD2. This altered activation
threshold induced by LFA-1 antagonism in humans is distinct
from anergy described in mouse models (Appleman and
Boussiotis, 2003), since (a) the suppression is antigen-
independent, as demonstrated by CD2 and CD3 effects; (b)
the hyporesponsiveness is spontaneously reversible upon
washout of the drug; and (c) Ca2þ flux is preserved after CD3
ligation. However, similar to true anergy, hyporesponsiveness
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in efalizumab-treated patients was instantly reversible
with IL-2.
We excluded other explanations for this reduced T-cell
activation, such as depletion of reactive T-cell populations or
reduced T-cell activation potential. Efalizumab-treated psor-
iasis patients have increased circulating T cells, so it is
unlikely that there would be depletion of reactive T cells
(Vugmeyster et al., 2004), and furthermore, the cells were
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viable (annexin V/propidium iodide staining; data not shown)
and fully activatable by PMA/ionomycin. Peripheral CLAþ T
cells were not investigated, although it might be interesting to
consider this T cell subset in a future study.
Efalizumab is efficacious in treating psoriasis and it is
assumed that key mechanisms of action include reduced
migration of T cells into the skin, as well as reduced T-cell
activation through interference with immune synapse forma-
tion between T cells and antigen-presenting cells, as
suggested by animal models (Ferrara et al., 1990; Isobe
et al., 1992; Scheynius et al., 1993; Tanaka et al., 1993;
Gordon et al., 1995; Moriyama et al., 1996; Willenborg et al.,
1996). In superantigen T-cell activation experiments from
psoriasis patients, T-cell activation was also reduced
(unpublished data), possibly reflecting interference with
immune synapse formation. Here, we demonstrate reduced
T-cell responsiveness independent of immune synapse
formation, suggesting a direct effect on T cells.
The mechanism of this reduced responsiveness is
important to understand. If conventional anergy and possibly
tolerance can be induced by ‘‘signal 1 without signal 2’’
(Schwartz, 1990; Huppa et al., 2003; Jenkinson et al., 2005;
Lin et al., 2005), it is possible that efalizumab-induced effects
are caused by ‘‘signal 2 without signal 1’’. One model of
T-cell activation via the immune synapse has LFA-1 serving to
increase initial adhesion, with main signal transduction
occurring via the TCR complex (Huppa et al., 2003).
However, it is now clear that LFA-1 also is capable of
directly transducing distinct activation signals. Hence, liga-
tion of LFA-1 by efalizumab might deliver signals (signal 2)
that make a T-cell hyporesponsive to later T-cell activation
signals delivered via the TCR/CD3 complex (signal 1).
Broad re-organization of activation-controlling surface
molecules on T cells is also produced by efalizumab. In vivo
efalizumab administration leads to down-modulation not
only of CD11a/CD18 as expected (Gottlieb et al., 2002;
Vugmeyster et al., 2004), but also of multiple surface
molecules, which may be involved in T-cell activation,
including CD3, TCR, CD4, CD8, CD28, and the integrin
VLA-4. This occurs in T cells both in the peripheral
circulation as well as in the tissue, although the effect is
more restricted in the tissue. Possible mechanisms of down-
regulation of such an extensive array of surface molecules
include capping of surface molecules by efalizumab (Mor-
tensen et al., 2005), alteration of cytoskeletal components
that are involved in immune synapse formation such as talin,
or incorporation of surface molecules into lipid rafts (Hogg
et al., 2003; Kinashi, 2005). T-cell activation often leads to
incorporation of integrins into lipid rafts and other membrane
proteins may complex with the integrins for colocalization
within the rafts (Meiri, 2005). There is now evidence that
efalizumab clearance is, at least partially, mediated by
internalization via CD11a, which supports such a hypothesis
(Coffey et al., 2005).
These data provide insight into the mechanism of action of
efalizumab contributing to its effect on T-cell-mediated
autoimmune diseases such as psoriasis. Moreover, there
are interesting conclusions to be made with regards to the
response to self- and foreign neo- and recall antigens.
However, the mechanism of downregulation of these surface
molecules is difficult to assess because we are unable to
reproduce these findings in vitro by incubation of peripheral
blood with efalizumab (unpublished data). If efalizumab
induced specific antigen-dependent anergy, it could be
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Figure 6. Down-modulation of VLA-4 and CD8 in peripheral blood CD8þ T cells in efalizumab-treated psoriatic patients. (a) Histograms for a representative
patient illustrate bimodal distribution of VLA-4 (CD49d/CD29) at baseline (gray line) on CD8þ cells, and a subsequent shift in VLA-4hi/VLA-4lo ratio
after 2 weeks of treatment. (b) Individual patient data were used to calculate the mean CD49d MFI for each time point and for each CD3þCD8þ subset, as
indicated. Dotted line corresponds to baseline CD49d MFI value for the CD49dlo subset. (c) CD8 levels on all CD3þCD8þ cells were quantified throughout
the treatment period (12 weeks) and upon efalizumab washout.
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speculated that long-lasting tolerance even beyond efalizu-
mab presence could be induced. Our data do not support this
hypothesis, but rather suggest a transient decrease in T-cell
activation, which is reversible by IL-2 exposure or by
antibody withdrawal.
Indeed, in a recent human trial (Genentech ACD2244g)
investigating the immune response to model antigens during
efalizumab in psoriasis patients, T-cell-dependent antibody
responses to the specific model neoantigen bacteriophage
fX174 were greatly reduced during treatment, but responses
to repeated administration of the same antigen normalized
after withdrawal without tolerance induction, contradicting
previous data from murine studies (Fischer et al., 1986;
Benjamin et al., 1988; Krueger et al., 2005) ( JG Krueger
et al. Effect of therapeutic integrin (CD11a) blockade with
efalizumab on immune responses to model antigens in
humans. Manuscript submitted for J Immunol, 2007). Taken
together, these data emphasize the extent to which T-cell
responses are blocked in efalizumab-treated patients and are
in good agreement with the results of this study.
We observed that T-cell responses to CD3/CD28
co-ligation were less suppressed than cell activation via
CD3 or CD2 alone, suggesting that secondary immune
responses in efalizumab-treated patients could be less
impacted by treatment. Consistent with this observation, the
human immunization trial demonstrated only a moderate
reduction, but not abrogation, of responses to skin recall
antigens measured by delayed-type hypersensitivity testing.
The unique set of cellular effects seen with efalizumab is
clearly distinct from the genetic defects of b2-integrins in
humans (leukocyte adhesion deficiency) or mice (Hogg and
Bates, 2000; Shaw et al., 2001; Bunting et al., 2002). Overall
we have observed unexpected cellular immune effects of
LFA-1 antagonism, which are different from those reported in
any model system, and could not have been predicted from
animal studies. Given the emerging role of the IL-17 pathway
in psoriasis (Lowes et al., 2007), future studies to evaluate the
therapeutic effects of efalizumab on this pathway will be
considered.
MATERIALS AND METHODS
Study design
Fourteen patients (11 males, 3 females, ages 28–59 years, median 48
years) and 17 patients (4 males, 13 females, ages 29–71, median 47
years) with moderate to severe psoriasis were enrolled in two
consecutive studies, study 1 and study 2, respectively, which were
approved by the Rockefeller University Hospital Institutional Review
Board. All patients were consented and the study was conducted
according to the Declaration of Helsinki Principles. The patients
were treated with weekly, subcutaneous efalizumab at 1mg kg1 per
week for 12 weeks, and followed for an additional 12 weeks.
A range of clinical responses to efalizumab therapy was observed,
from complete clearing of psoriasis to minimal improvement. One
and two patients withdrew from the first and second studies,
respectively, and did not have final biopsies. Five healthy volunteers
(2 males, 3 women, ages 20–68, median 46 years) were also enrolled
for assessing the dose-dependent activation response to efalizumab
treatment in vitro. Response was determined both histologically and
clinically, as previously described (Wittkowski, 2004; Lowes et al.,
2005). In study 1, 11 patients were categorized as responders and
two as non-responders. In study 2, 11 patients were categorized as
responders and four as non-responders.
Skin biopsies
Skin biopsies were obtained at baseline and 2 weeks after the first
dose and processed as previously described (Ferenczi et al., 2002).
Briefly, skin samples were cut into small pieces and placed in 5mM
EDTA (Fisher Scientific, Pittsburgh, PA) acid at 4 1C (pH 7) for 4 hours
with continuous gentle agitation. The resultant cell suspension was
filtered through a nylon mesh filter, centrifuged, washed with
phosphate-buffered saline, and resuspended at 105 cellsml1 for
staining and analysis by FACS.
Peripheral blood samples
Peripheral blood draws were taken at baseline and at either 2, 12,
and 24 weeks (study 1) or at 24 hours, 2, 6, and 12 weeks (study 2).
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized samples by using standard Ficoll–Hypaque (Pharmacia
Biotech, Uppsala, Sweden) density-gradient sedimentation. For
study 1, whole blood was used for activation assay, whereas PBMCs
were used for T-cell phenotype by FACS, with the exception of
CD11a expression for which both whole blood and PBMCs were
analyzed. For study 2, PBMCs were used for activation assays, FACS,
and Ca2þ flux experiments, whereas whole blood was used to
determine cytokine production and T-cell phenotype by FACS.
Whole blood and PBMC activation assays
Heparinized whole blood was incubated with either 1mgml1 of
mouse anti-CD3 antibody (clone UCHT1; PharMingen, San Diego,
CA) overnight at 37 1C in the presence of varying dilutions
(0.0001–100mgml1) of efalizumab (in vitro assay; Figure 1a);
1.6–1,000ngml1 of mouse anti-CD3 antibody (clone UCHT1)
overnight at 37 1C (ex vivo assay; Figure 2a); or 25 ngml1 PMA,
2mgml1 ionomycin, and 10 mgml1 brefeldin A for 4 hours at 37 1C
(ex vivo assay; Figure 2e and f). Upon red blood cell lysis (168mM
NH4Cl, 10mM KHCO3, 0.089mM Na4EDTA), cells were stained with
anti-CD2 FITC and anti-CD69 phycoerythrin (PE)-cy5 (Becton
Dickinson, San Jose, CA (BD)). Geometric mean fluorescent intensity
(GMFI) or MFI of CD69 on CD2þ lymphocytes was determined by
FACS analysis for the in vitro assay (Figure 4a) or ex vivo assay (study
1; Figure 4a, e, f), respectively. For the in vitro assay, percent
inhibition was calculated. The IC50 was calculated using a
four-parameter curve fit in KaleidaGraph Software.
For study 2 (Figure 1c and d), PBMCs were activated for 4hours at
37 1C, using 1mgml1 of the OKT3 antibody (anti-CD3) (OrthoBiotech,
Bridgewater, NJ), 0.5mgml1 T11.1þ 0.5mgml1 T11.2 (anti-CD2)
(Immunotech, Cedex, France), or anti-CD3/CD28 Dynabeads (Dynal
Biotech, Invitrogen Corp., Carlsbad, CA) (three beads per T cell) in the
presence of 10mgml1 brefeldin A (Sigma Aldrich, St Louis, MO). After
removing Dynabeads on Dynal magnetic particle concentrator, PBMCs
were washed with FACSWash (2% fetal bovine serum in phosphate-
buffered saline, 0.1% sodium azide (Sigma Aldrich)), and permeabi-
lized using FACSPerm (BD). MFI of CD69 on CD3 lymphocytes (with
anti-CD3 clone SK7 that does not directly compete with OKT3 for
T-cell binding) was determined by FACS analysis. Two out of 14 and
two of 17 patients in study 1 and study 2, respectively, were excluded
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in calculations of the mean, as they had baseline (day 0) T-cell
activation below the acceptance criteria (less than 15% CD69 T cells)
or had missing samples.
Peripheral blood lymphocyte proliferation assay using healthy
volunteers
Cell proliferation was determined using 3H-labeled thymidine
incorporation as previously described (van Kooyk et al., 1996; Khanna
and Hosenpud, 1999). Briefly, 96-well plates were coated for 1hour at
37 1C with suboptimal concentration of anti-CD3 (T3b, 0.07mgml1) or
anti-CD3 (0.07mgml1)þ anti-CD28 (0.125mgml1), followed by goat-
anti-human Fc (400ngwell1, 1hour at 37 1C), 1% BSA (100mlwell1,
30minutes at 37 1C), and efalizumab (100ngwell1, 1hour at 37 1C), as
described previously (van Kooyk et al., 1996). Resting peripheral blood
lymphocytes were added (100000cellswell1) and cultured for 3 days,
as described previously (van Kooyk et al., 1996). On day 3, cells were
pulsed for 16hours with 3H-labeled thymidine (1.52TBqmmol1,
0.5mCiwell1; Amersham Corp., Arlington Heights, IL), and uptake was
quantified to measure cell proliferation in the presence of either
efalizumab, MHM24 (efalizumab parent monoclonal murine non
humanized antibody), or the Fab fragment of efalizumab (all at
0.07mM, from Genentech Inc., South San Francisco, CA).
Whole-blood cytokine analysis
Heparinized whole blood was activated for 4 hours using either anti-
CD3 (1mgml1 OKT3), anti-CD2 (0.5 mgml1 T11.1þ 0.5 mgml1
T11.2), anti-CD3/CD28 Dynabeads, or PMA/ionomycin (25 ngml1
PMA, 2mgml1 ionomycin), and 10 mgml1 brefeldin A. Samples
were treated with 2mM EDTA for 10minutes at room temperature
(RT). Red blood cells were then lysed with FACSLyse solution (BD)
and centrifuged and washed to obtain PBMCs, which were frozen in
media containing RPMI medium 1640 (Gibco/BRL, Rockville, MD),
with 1mM HEPES buffer (Sigma Aldrich), 0.1% gentamycin (Gibco/
BRL), and 5% normal human serum (C-Six Diagnostic, Germantown,
WI) with 10% dimethyl sulfoxide. Unactivated controls were
processed in parallel. Before cytokine staining, PBMCs were thawed,
washed, and permeabilized with FACSPerm. The fraction of
IFNg-producing T cells (SK7þ lymphocytes) was determined by
flow cytometry. Percent change in IFNg-producing ability was
calculated.
FACS analysis
FACS was used to analyze heparinized whole blood, PBMCs, or
single cell suspensions from skin biopsies. When whole blood was
used, cells were stained with antibodies for 10minutes at RT, lysed
with FACSLyse for 10minutes at RT, and washed with FACSWash.
PBMCs were stained for 15minutes at RT. The following antibodies
were used: CD18 (PE), CD3 (PerCP), CD2 (FITC), TCR (FITC), CD49d
(PE), CD29 (FITC), CD4 (FITC), CD8 (Per) CD25 (PE), CD28 (PE),
CD69 (FITC), IFN-g (FITC), and IL-2 (FITC) (BD). Staining for CD11a
was performed with two different anti-CD11a mAbs: efalizumab–-
FITC (Genentech, custom design) and clone 25.3-FITC (Immuno-
tech). Appropriate IgG isotype controls were added (BD). Cells were
washed with FACSWash and resuspended in 1.3% formaldehyde
(Fisher Scientific) in FACSWash. Samples were analyzed with four-
color staining using a FACSCalibur Flow Cytometer and CELLQuest
software after calibration with CaliBRITE beads and FACSComp
software (BD).
Caþ 2 flux
PBMCs (107 per milliliter) were loaded with 2mM Indo-1 (Molecular
Probes, Invitrogen Corp., Carlsbad, CA) for 30minutes at 37 1C in
RPMI. The cells were washed with warm RPMI, resuspended in
RPMI at RT, and acquired at baseline using a BD LSR flow
cytometer. OKT3 (anti-CD3) (OrthoBiotech) activator was added
and after an additional 20 seconds, a cross-linking mouse IgG2a was
added. The Ca flux was measured as the ratio between bound and
unbound Indo-1 versus time.
Statistical analysis
Student’s t-test and two-sided sign test were performed, with the
assumption of equal probability of an increase or decrease from day
0 value. Significance was accepted as Po0.05.
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SUPPLEMENTARY MATERIAL
Figure S1. Anti-CD3-mediated intracellular Ca2þ flux response is normal in
T cells from efalizumab-treated patients.
Figure S2. Anti-CD3 and anti-CD2-mediated intracellular Ca2þ flux response
is normal in T cells from efalizumab-treated patients.
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